N/A
Completed N=308
Effects of Open-label vs Double-blind Treatment in IBS
Irritable Bowel Syndrome · Placebo Effect · Placebos · Peppermint Oil
Source: ClinicalTrials.gov NCT02802241 ↗
Enrolled (actual)
308
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcomePrimary: Change in Irritable Bowel Syndrome - Symptom Severity Score (IBS-SSS) From Baseline to Six Weeks. — 74.6; 94.6; 56.4; 90.8 score on a scale
Summary
The purpose of this study is to investigate placebo effects and peppermint oil in Irritable Bowel Syndrome.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Irritable Bowel Syndrome - Symptom Severity Score (IBS-SSS) From Baseline to Six Weeks. |
74.6; 94.6; 56.4; 90.8; 90.6; 100.3 | — |
Eligibility Criteria
Inclusion Criteria
- Meet Rome IV diagnostic criteria for IBS
Data sourced from ClinicalTrials.gov (NCT02802241). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.